Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus
Background: Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear. We investigate the relationship between total and bioactive sclerostin measured...
Saved in:
| Main Authors: | Cyril Traechslin, Lilian Sewing, Sandra Baumann, Leticia Grize, Janina Vavanikunnel, Marius Kraenzlin, Christoph Henzen, Christian Meier |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Clinical & Translational Endocrinology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623725000110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum sclerostin in vascular calcification in CKD: a meta-analysis
by: Yan Lin, et al.
Published: (2023-12-01) -
Progress of studies on sclerostin’s role in vascular calcification of chronic kidney disease
by: PENG Qiong-yao, et al.
Published: (2019-01-01) -
The serum levels of FGF23, sclerostin, osteoprotegerin do not explain the inverse relationship between coronary calcifications and bone mineral density evaluated using computed tomography
by: Laurence Ferrières, et al.
Published: (2025-06-01) -
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
by: Shi-Hsun Chiu, et al.
Published: (2024-12-01) -
Sclerostin as a new target of diabetes-induced osteoporosis
by: Yanhua Li, et al.
Published: (2024-12-01)